Abstract: A sustained release dosage form includes a capsule made of a thermoplastic polymer having a softening point below 200° C. and an orifice formed or formable within the capsule, an emulsion formulation contained within the capsule, and an expandable composition within the capsule remote from the orifice. The emulsion formulation comprises a drug, an emulsifying surfactant, and an oil. The expandable composition is configured to expand and expel the emulsion formulation through the orifice.

Abstract: A dosage form is disclosed comprising a drug formulation that self-emulsifies in the drug formulation.

Abstract: A composition is disclosed comprising a polymer and a surfactant in a solvent exhibiting a common solubility for the polymer and the surfactant. The composition provides a dosage form for administering a drug over time.

Abstract: A composition is disclosed comprising a polymer and a surfactant in a solvent exhibiting a common solubility for the polymer and the surfactant. The composition provides a dosage form for administering a drug over time.

Abstract: Controlled release of self-dispersing nanoparticle active agent formulations is provided by dispersing porous particles into which have been sorbed a self-dispersing nanoparticle active agent formulation in osmotic, push-layer dosage forms. The dosage forms may provide for continuous or pulsatile delivery of active agents.

Abstract: This invention pertains to the enhanced delivery of orally administered pharmaceutical agents and methods, dosage forms and devices thereof. In particular, the invention is directed to methods including providing a low solubility drug having a pKa between about 6 and about 9; dissolving the low solubility drug in an aqueous solution, wherein a pH of the aqueous solution is less than about 6.0; dissolving a hydrophilic polymer in the aqueous solution, wherein the weight ratio of the hydrophilic polymer to the low solubility drug is less than or equal to about 0.15; lyophilizing the aqueous solution to obtain a lyophilized powder. Also disclosed are drug formulations made according to the method, and dosage forms that include the drug formulations.

Abstract: The present invention includes a dosage form configured to provide the controlled release of an active agent formulation. A dosage form according to the present invention includes a reservoir containing an active agent formulation and an engine positioned at least partially within the reservoir. In order to reduce the possibility that the engine included in a dosage form of the present invention will separate from the reservoir either during or after fabrication, the dosage form of the present invention includes a band that binds the engine to the reservoir. The band is provided over an outside surface of the both the engine and the reservoir at or near the interface formed where the engine enters the opening provided in the reservoir. The present invention also includes a method of fabricating controlled release dosage forms having banded engine.

Abstract: The present invention relates to osmotic engines and dosage forms providing the controlled release of a liquid active agent formulation. More specifically, the present invention is directed to osmotic engines, dosage forms and methods that preserve osmotic engine functionality and reduce void volume formation in osmotically driven dosage form providing the controlled release of liquid active agent formulations.

Abstract: A composition is disclosed comprising a polymer and a surfactant in a solvent exhibiting a common solubility for the polymer and the surfactant. The composition provides a dosage form for administering a drug over time.

Abstract: A dosage form manufactured from an extruded polymer tube and method for manufacturing the dosage form are disclosed. The dosage form is preferably an osmotic dosage form and includes a therapeutic agent and an expandable composition contained within the lumen of the extruded polymer tube.

Abstract: The present invention includes an expandable osmotic layer and a coating suspension for providing an expandable osmotic layer, both of which are useful for the manufacture of controlled release dosage forms. The expandable osmotic layer of the present invention may be produced using the coating suspension of the present invention. Advantageously, the coating suspension of the present invention can be used to coat expandable osmotic layers under both wet and dry process conditions without sacrificing the quality of the expandable osmotic layers produced, and therefore provides a relatively robust coating suspension that facilitates commercial production of controlled release dosage forms including a coated expandable osmotic layer.

Abstract: A dosage form is disclosed comprising a semipermeable walled container that houses a capsule, which capsule comprises a drug formulation, a piston, and an osmotic composition. The dosage form delivers the drug formulation through a passageway at a controlled rate over a sustained-release period of time up to 24 hours.

Abstract: A dosage form is disclosed comprising a semipermeable walled container that houses a capsule, which capsule comprises a drug formulation, a piston, and an osmotic composition. The dosage form delivers the drug formulation through a passageway at a controlled rate over a sustained-release period of time up to 24 hours.

Abstract: The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a polymer matrix that swells upon contact with the fluids of the stomach. A portion of the polymer matrix is surrounded by a band of insoluble material that prevents the covered portion of the polymer matrix from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed.

Abstract: A dosage form manufactured from an extruded polymer tube and method for manufacturing the dosage form are disclosed. The dosage form is preferably an osmotic dosage form and includes a therapeutic agent and an expandable composition contained within the lumen of the extruded polymer tube.

Abstract: A dosage form manufactured from an extruded polymer tube and method for manufacturing the dosage form are disclosed. The dosage form is preferably an osmotic dosage form and includes a therapeutic agent and an expandable composition contained within the lumen of the extruded polymer tube.

Abstract: A dosage form is disclosed comprising a drug formulation that self-emulsifies in said dosage form.

Abstract: A dosage form is disclosed comprising a drug formulation that self-emulsifies in said dosage form.

Abstract: Polymeric compositions are disclosed comprising a poly(caprolactone), a poly(alkylene oxide), a poly(oxyethylenated fatty acid ester), or a poly(oxyethylenated fatty acid), or a poly(oxyethylene-co-oxypropylene).

Abstract: The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a polymer matrix that swells upon contact with the fluids of the stomach. A portion of the polymer matrix is surrounded by a band of insoluble material that prevents the covered portion of the polymer matrix from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed.